Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

In a recent phase 1 study, zilebesiran, an investigational RNA interference therapeutic agent, demonstrated potential in treating hypertension. The study included 107 patients with hypertension, who received a single ascending subcutaneous dose of zilebesiran (ranging from 10 to 800 mg) or placebo for 24 weeks. Results showed dose-dependent reductions in serum angiotensinogen levels and 24-hour ambulatory blood pressure, sustained for up to 24 weeks with 200 mg or higher doses. Mild injection-site reactions were observed, but there were no major safety concerns. Zilebesiran could hold promise as a prolonged-action hypertension therapy.